Home Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics Announces Definitive Agreement to Be Acquired by Siemens Healthineers

Mark J. Toland, President and Chief Executive Officer of Corindus. “We believe the transaction will deliver immediate, compelling and certain value to all Corindus stockholders, as well as substantial benefits to our customers.

CorPath® GRX Systems Installed at HCA Healthcare Facilities

The new systems are now installed in hospital locations in Florida and Texas, bringing the total number of HCA hospitals utilizing CorPath GRX to three.

5/7/19: Chesapeake Regional Medical Center Installs CorPath GRX Vascular Robotic Systems in All Cath Labs

Chesapeake Regional Medical Center has installed the CorPath GRX Vascular Robotic Systems in all catheterization labs.

Corindus Announces FDA Submission for Neurovascular Intervention Indication for CorPath® GRX Vascular Robotic System

2/14/19: An expansion of CorPath GRX Vascular Robotic System to treat neurovascular conditions would represent a major stepping stone towards our goal of revolutionizing stroke treatment,” said Mark Toland, President and Chief Executive Officer of Corindus.

Corindus to Feature Recent Advancements in Robotic Technology at SCAI 2018 Scientific Sessions

4/23/18: Optimizing care with CorPath GRX: Hot topics in robotic interventions.

Corindus Receives FDA Clearance for First Automated Robotic Movement in technIQ™ Series for CorPath GRX Platform

3/5/18: -Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for the CorPath GRX platform.

Corindus Receives FDA Clearance for CorPath® GRX System in Peripheral Vascular Interventions

2/20/18: Corindus Vascular Robotics, Inc. (NYSE American:CVRS), a leading developer of precision vascular robotics, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration for use of its CorPath GRX System in peripheral vascular interventions. The CorPath System is the first and only FDA-cleared medical device to bring robotic precision to both percutaneous coronary intervention and peripheral vascular intervention procedures.

Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians

12/1/17: Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath GRX Systems.